On the Analysis of Cyclic Drug Schedules for Cancer Treatment using Switched Dynamical Systems
暂无分享,去创建一个
Claire J. Tomlin | Margaret P. Chapman | Rosalie C. Sears | Eric V. Mazumdar | Ellen Langer | C. Tomlin | R. Sears | E. Langer
[1] Anders Rantzer,et al. Computation of piecewise quadratic Lyapunov functions for hybrid systems , 1997, 1997 European Control Conference (ECC).
[2] S. Rinaldi,et al. Positive Linear Systems: Theory and Applications , 2000 .
[3] Jamal Daafouz,et al. Stability analysis and control synthesis for switched systems: a switched Lyapunov function approach , 2002, IEEE Trans. Autom. Control..
[4] Hai Lin,et al. Switched Linear Systems: Control and Design , 2006, IEEE Transactions on Automatic Control.
[5] Hai Lin,et al. Stability and Stabilizability of Switched Linear Systems: A Survey of Recent Results , 2009, IEEE Transactions on Automatic Control.
[6] Xingwen Liu,et al. Stability Analysis of Switched Positive Systems: A Switched Linear Copositive Lyapunov Function Method , 2009, IEEE Transactions on Circuits and Systems II: Express Briefs.
[7] Franco Blanchini,et al. Discrete‐time control for switched positive systems with application to mitigating viral escape , 2011 .
[8] Guy S. Salvesen,et al. SnapShot: Caspases , 2011, Cell.
[9] A. Tolcher,et al. The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer , 2012, Clinical Cancer Research.
[10] A. Bardelli,et al. Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas , 2012, Clinical Cancer Research.
[11] Patrizio Colaneri,et al. Optimal therapy scheduling for a simplified HIV infection model , 2013, Autom..
[12] Patrizio Colaneri,et al. Switching Strategies to Mitigate HIV Mutation , 2014, IEEE Transactions on Control Systems Technology.
[13] E. Van Cutsem,et al. A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors , 2014, Clinical Cancer Research.
[14] P. Majumder,et al. Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition , 2015, Nature Communications.
[15] E. Jokinen,et al. MEK and PI3K inhibition in solid tumors: rationale and evidence to date , 2015, Therapeutic advances in medical oncology.
[16] Raja R Srinivas,et al. Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution , 2016, Cell.
[17] J. Grilley-Olson,et al. A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors , 2016, Investigational New Drugs.
[18] Claire J. Tomlin,et al. A model of phenotypic state dynamics initiates a promising approach to control heterogeneous malignant cell populations , 2016, 2016 IEEE 55th Conference on Decision and Control (CDC).
[19] J. Tabernero,et al. A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer , 2017, Targeted Oncology.